SGN CD70A

Drug Profile

SGN CD70A

Alternative Names: SGN 70A; SGN-CD70A

Latest Information Update: 02 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seattle Genetics
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Alkylating agents; CD70 antigen inhibitors; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 27 Oct 2016 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 27 Oct 2016 Discontinued - Phase-I for Renal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 12 Aug 2014 Phase-I clinical trials in Non-Hodgkin's lymphoma (Refractory metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02216890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top